Infants and children are among the most vulnerable to infectious diseases. Biotech therapies have helped prevent some of the most dangerous childhood conditions, increasing life expectancy, reducing costs of care and avoiding immeasurable suffering.
Protecting Infants from RSV
By two years old, all children are infected with severe respiratory syncytial virus (RSV). For most, RSV results in a simple cold. But for young infants with lung problems, RSV can be a life-threatening condition. Each year, RSV kills 500 American infants. The estimated direct medical cost of RSV-associated hospital care is $750 million annually. Synagis® (MedImmune), protects infants from RSV, saving lives and money.